Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Atavistik Bio, Inc
BeOne Medicines
Eli Lilly and Company
Terremoto Biosciences Inc.
Incyte Corporation
Avenzo Therapeutics, Inc.
Incyclix Bio
Dana-Farber Cancer Institute
OHSU Knight Cancer Institute
Pfizer
University of California, San Francisco
Syros Pharmaceuticals